Underpinned by the successful clinical application of GLP-1 receptor agonists and dipeptidyl peptisase-4 inhibitors to the management of type 2 diabetes (5, 11, 12), there has been great interest in the potential for BTR agonists to augment L-cell secretion, and thereby increase concentrations of endogenous GLP-1. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.